15 years of anti-VEGF treatment for nAMD: success or failure or something in between?
作者信息
Chakravarthy Usha, Armendariz Beatriz G, Fauser Sascha
机构信息
Centre for Public Health, Institute of Clinical Science, Royal Victoria Hospital, Queens University of Belfast, Belfast, BT12 6BA, UK.
Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
出版信息
Eye (Lond). 2022 Dec;36(12):2232-2233. doi: 10.1038/s41433-022-02153-9. Epub 2022 Jun 25.
Abstract
摘要
相似文献
1
15 years of anti-VEGF treatment for nAMD: success or failure or something in between?
Eye (Lond). 2022 Dec;36(12):2232-2233. doi: 10.1038/s41433-022-02153-9. Epub 2022 Jun 25.
2
Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
Acta Ophthalmol. 2015 Dec;93(8):734-8. doi: 10.1111/aos.12770. Epub 2015 May 28.
3
Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
J Med Econ. 2021 Jan-Dec;24(1):1087-1097. doi: 10.1080/13696998.2021.1971416.
4
A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).
Health Technol Assess. 2015 Oct;19(78):1-298. doi: 10.3310/hta19780.
5
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
BMC Ophthalmol. 2021 Feb 17;21(1):90. doi: 10.1186/s12886-021-01841-6.
6
Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.
Ophthalmology. 2017 Feb;124(2):224-234. doi: 10.1016/j.ophtha.2016.10.010. Epub 2016 Oct 28.
7
Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
Jpn J Ophthalmol. 2021 Nov;65(6):741-760. doi: 10.1007/s10384-021-00869-x. Epub 2021 Sep 7.
8
Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis.
BMJ Open. 2020 Dec 29;10(12):e042484. doi: 10.1136/bmjopen-2020-042484.
9
Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina.
Cutan Ocul Toxicol. 2021 Jun;40(2):135-139. doi: 10.1080/15569527.2021.1919136. Epub 2021 May 4.
10
The port delivery system with ranibizumab: understanding nuances for clinical use in the real world.
Expert Opin Biol Ther. 2022 Jun;22(6):675-677. doi: 10.1080/14712598.2022.2078162. Epub 2022 May 23.
引用本文的文献
1
Early Real-World Outcomes of Switching to 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration in the United Kingdom.
Life (Basel). 2025 Jun 2;15(6):903. doi: 10.3390/life15060903.
2
Novel Therapeutic Approaches for Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration.
Vision (Basel). 2025 Apr 17;9(2):35. doi: 10.3390/vision9020035.
3
Assessing variation in US payer coverage of anti-vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema.
J Manag Care Spec Pharm. 2025 May;31(5):451-460. doi: 10.18553/jmcp.2025.24340. Epub 2025 Apr 3.
4
Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis.
Ophthalmol Ther. 2025 Apr;14(4):733-753. doi: 10.1007/s40123-025-01098-y. Epub 2025 Feb 24.
5
Photoreceptor Degeneration: More Than a Bystander in Age-Related Macular Degeneration.
Adv Exp Med Biol. 2025;1468:27-31. doi: 10.1007/978-3-031-76550-6_5.
6
Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab.
Front Med (Lausanne). 2025 Jan 15;11:1467160. doi: 10.3389/fmed.2024.1467160. eCollection 2024.
7
Resveratrol Supplementation in Wet AMD: Association With Fewer Intravitreal Injections and Reduced Macular Fibrosis.
Clin Ophthalmol. 2025 Jan 21;19:217-225. doi: 10.2147/OPTH.S494595. eCollection 2025.
8
Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration.
Ophthalmol Ther. 2025 Jan;14(1):211-228. doi: 10.1007/s40123-024-01061-3. Epub 2024 Dec 14.
9
Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort.
J Biol Chem. 2024 Jul;300(7):107452. doi: 10.1016/j.jbc.2024.107452. Epub 2024 Jun 7.
10
Vascular Cell Adhesion Molecule-1 (VCAM-1) contributes to macular fibrosis in neovascular age-related macular degeneration through modulating macrophage functions.
Immun Ageing. 2023 Nov 20;20(1):65. doi: 10.1186/s12979-023-00389-x.
本文引用的文献
1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24.
2
Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy.
Genes Dis. 2021 Feb 27;9(1):62-79. doi: 10.1016/j.gendis.2021.02.009. eCollection 2022 Jan.
3
Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration.
Sci Rep. 2022 Jan 7;12(1):88. doi: 10.1038/s41598-021-03716-8.
4
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2022 Mar;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016. Epub 2021 Sep 29.
5
The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results.
Ophthalmol Ther. 2021 Dec;10(4):935-945. doi: 10.1007/s40123-021-00381-y. Epub 2021 Aug 9.
6
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15.
7
Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2020 Oct;127(10):1360-1370. doi: 10.1016/j.ophtha.2020.03.031. Epub 2020 Apr 2.
8
Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial.
Ophthalmology. 2020 Sep;127(9):1191-1200. doi: 10.1016/j.ophtha.2020.03.020. Epub 2020 Mar 27.
9
Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset.
Ophthalmologica. 2020;243(1):1-8. doi: 10.1159/000502747. Epub 2019 Nov 19.
10
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Ophthalmology. 2020 Feb;127(2):186-195. doi: 10.1016/j.ophtha.2019.07.011. Epub 2019 Jul 16.
Zotero 插件